Adjuvanted subunit intranasal vaccine reduces SARS-CoV-2 onward transmission in hamsters
Overall, our study strongly supports the use of the intranasal vaccine as a boost to protect not only the vaccinated person, but also people exposed to the vaccinated person, a key public health goal.
Authors
- Shannon M. Wallace (ORCID: https://orcid.org/0009-0008-6735-4969)
- Yongjun Sui (ORCID: https://orcid.org/0000-0002-1568-4607)
- Swagata Kar (ORCID: https://orcid.org/0000-0003-3702-6207)
- Tanya Hoang
- Bhavna Chawla (ORCID: https://orcid.org/0009-0001-7759-122X)
- YuanKai Yu
- Hanné Andersen
- Jay A. Berzofsky
Institutions
- National Institutes of Health (US)
- Experimental Pathology Laboratories (US)
- Bioqual (US)
- National Cancer Institute (US)
- Cancer Genetics (United States) (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-02-07
- DOI
- https://doi.org/10.3389/fimmu.2025.1514845
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- National Institutes of Health
- National Cancer Institute